Filing Flows › DataMeds AI (MEDS) › Q1 2026
DataMeds AI (MEDS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 19, 2026
DataMeds AI (MEDS) reported revenue of $1.6M for the first quarter 2026 (Q1 2026), -86% from a year earlier and -7% from the quarter before. Operating margin was -385.7%, net loss $7.7M (496.5% of revenue).
DataMeds AI, Q1 2026: revenue $1.6M (-86% year over year), operating margin -385.7%, net loss $7.7M, operating cash flow −$3.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -7% | -86% |
| Operating profit | −$6.0M | — | — |
| Net earnings | −$7.7M | — | — |
| Operating cash flow | −$3.4M | — | — |
What changed
Revenue was $1.6M in Q1 2026, down 86% year over year and down 7% from the previous quarter. Pharmacy Retail Sales was the largest line at 73% of revenue. Product lost $10.4M year over year (down 98%), 112% of the total change.
Gross margin was 10.9%, up 4.5 points from Q1 2025. Operating costs exceeded revenue by $6.0M, an operating margin of -385.7%. Operating expenses fell 81% while revenue fell 86%. The fastest-growing cost line was Sales & marketing (+1372%). The quarter ended with a net loss of $7.7M, narrower than the previous quarter's $27.9M loss.
Operating cash flow was −$3.4M. Non-cash charges added back $357K of depreciation and amortization and $1.4M of share-based compensation. Working capital and other items added $2.6M.
Questions
What was DataMeds AI's revenue in the first quarter 2026?
DataMeds AI (MEDS) reported revenue of $1.6M for the first quarter 2026 (Q1 2026), -86% from a year earlier and -7% from the quarter before.
Was DataMeds AI profitable in the first quarter 2026?
Operating loss was $6.0M (-385.7% of revenue) and net loss $7.7M.
Source: DataMeds AI 10-Q on SEC EDGAR.